PBYI
Price
$3.00
Change
-$0.03 (-0.99%)
Updated
Apr 24, 04:59 PM (EDT)
Capitalization
149.33M
7 days until earnings call
RARE
Price
$37.63
Change
+$0.32 (+0.86%)
Updated
Apr 24, 04:59 PM (EDT)
Capitalization
3.37B
7 days until earnings call
Ad is loading...

PBYI vs RARE

Header iconPBYI vs RARE Comparison
Open Charts PBYI vs RAREBanner chart's image
Puma Biotechnology
Price$3.00
Change-$0.03 (-0.99%)
Volume$1.58K
Capitalization149.33M
Ultragenyx Pharmaceutical
Price$37.63
Change+$0.32 (+0.86%)
Volume$54.43K
Capitalization3.37B
PBYI vs RARE Comparison Chart
Loading...
PBYI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RARE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
PBYI vs. RARE commentary
Apr 25, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is PBYI is a Hold and RARE is a Buy.

Ad is loading...
COMPARISON
Comparison
Apr 25, 2025
Stock price -- (PBYI: $3.02 vs. RARE: $37.31)
Brand notoriety: PBYI and RARE are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: PBYI: 54% vs. RARE: 112%
Market capitalization -- PBYI: $149.33M vs. RARE: $3.37B
PBYI [@Biotechnology] is valued at $149.33M. RARE’s [@Biotechnology] market capitalization is $3.37B. The market cap for tickers in the [@Biotechnology] industry ranges from $266.85B to $0. The average market capitalization across the [@Biotechnology] industry is $2.09B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

PBYI’s FA Score shows that 1 FA rating(s) are green whileRARE’s FA Score has 0 green FA rating(s).

  • PBYI’s FA Score: 1 green, 4 red.
  • RARE’s FA Score: 0 green, 5 red.
According to our system of comparison, PBYI is a better buy in the long-term than RARE.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

PBYI’s TA Score shows that 4 TA indicator(s) are bullish while RARE’s TA Score has 5 bullish TA indicator(s).

  • PBYI’s TA Score: 4 bullish, 5 bearish.
  • RARE’s TA Score: 5 bullish, 3 bearish.
According to our system of comparison, RARE is a better buy in the short-term than PBYI.

Price Growth

PBYI (@Biotechnology) experienced а +4.86% price change this week, while RARE (@Biotechnology) price change was +6.66% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +7.15%. For the same industry, the average monthly price growth was -6.00%, and the average quarterly price growth was -12.59%.

Reported Earning Dates

PBYI is expected to report earnings on Jul 31, 2025.

RARE is expected to report earnings on Jul 31, 2025.

Industries' Descriptions

@Biotechnology (+7.15% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
RARE($3.37B) has a higher market cap than PBYI($149M). PBYI YTD gains are higher at: -0.984 vs. RARE (-11.314). PBYI has higher annual earnings (EBITDA): 48.1M vs. RARE (-469M). RARE has more cash in the bank: 610M vs. PBYI (101M). RARE has less debt than PBYI: RARE (40.3M) vs PBYI (74.1M). RARE has higher revenues than PBYI: RARE (560M) vs PBYI (230M).
PBYIRAREPBYI / RARE
Capitalization149M3.37B4%
EBITDA48.1M-469M-10%
Gain YTD-0.984-11.3149%
P/E Ratio4.85N/A-
Revenue230M560M41%
Total Cash101M610M17%
Total Debt74.1M40.3M184%
FUNDAMENTALS RATINGS
PBYI vs RARE: Fundamental Ratings
PBYI
RARE
OUTLOOK RATING
1..100
1113
VALUATION
overvalued / fair valued / undervalued
1..100
43
Fair valued
74
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
2498
PRICE GROWTH RATING
1..100
6179
P/E GROWTH RATING
1..100
96100
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

PBYI's Valuation (43) in the Biotechnology industry is in the same range as RARE (74). This means that PBYI’s stock grew similarly to RARE’s over the last 12 months.

PBYI's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as RARE (100). This means that PBYI’s stock grew similarly to RARE’s over the last 12 months.

PBYI's SMR Rating (24) in the Biotechnology industry is significantly better than the same rating for RARE (98). This means that PBYI’s stock grew significantly faster than RARE’s over the last 12 months.

PBYI's Price Growth Rating (61) in the Biotechnology industry is in the same range as RARE (79). This means that PBYI’s stock grew similarly to RARE’s over the last 12 months.

PBYI's P/E Growth Rating (96) in the Biotechnology industry is in the same range as RARE (100). This means that PBYI’s stock grew similarly to RARE’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
PBYIRARE
RSI
ODDS (%)
N/A
Bullish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
67%
Momentum
ODDS (%)
Bullish Trend 2 days ago
84%
Bullish Trend 2 days ago
82%
MACD
ODDS (%)
Bullish Trend 2 days ago
81%
Bullish Trend 2 days ago
84%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
83%
Bullish Trend 2 days ago
76%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
85%
Bearish Trend 2 days ago
82%
Advances
ODDS (%)
Bullish Trend 2 days ago
84%
Bullish Trend 2 days ago
77%
Declines
ODDS (%)
Bearish Trend 8 days ago
86%
Bearish Trend 17 days ago
80%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
82%
Bullish Trend 2 days ago
83%
Aroon
ODDS (%)
Bearish Trend 2 days ago
83%
Bearish Trend 2 days ago
84%
View a ticker or compare two or three
Ad is loading...
PBYI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RARE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
AWSHX58.45N/A
N/A
American Funds Washington Mutual A
BRWVX21.36N/A
N/A
MFS Blended Research Growth Eq R6
HMEZX19.77N/A
N/A
NexPoint Merger Arbitrage Z
FLKSX13.83N/A
N/A
Fidelity Low-Priced Stock K6
FIDPX10.41N/A
N/A
Federated Hermes Intl Dividend Strategy

PBYI and

Correlation & Price change

A.I.dvisor indicates that over the last year, PBYI has been loosely correlated with RGNX. These tickers have moved in lockstep 37% of the time. This A.I.-generated data suggests there is some statistical probability that if PBYI jumps, then RGNX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PBYI
1D Price
Change %
PBYI100%
+0.33%
RGNX - PBYI
37%
Loosely correlated
+13.43%
COGT - PBYI
35%
Loosely correlated
+3.00%
MDGL - PBYI
34%
Loosely correlated
+2.01%
AURA - PBYI
34%
Loosely correlated
+0.88%
RARE - PBYI
34%
Loosely correlated
+3.90%
More

RARE and

Correlation & Price change

A.I.dvisor indicates that over the last year, RARE has been loosely correlated with CRNX. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if RARE jumps, then CRNX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RARE
1D Price
Change %
RARE100%
+3.90%
CRNX - RARE
49%
Loosely correlated
+3.55%
IONS - RARE
47%
Loosely correlated
+0.24%
RVMD - RARE
47%
Loosely correlated
+1.57%
VCYT - RARE
46%
Loosely correlated
+1.08%
DNLI - RARE
45%
Loosely correlated
+1.85%
More